Urgent.News

What's breaking now, across hundreds of outlets.

More in Finance & Markets

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?

Johnson & Johnson's drug-and-device product mix faces off against Pfizer's high-stakes oncology and obesity bets, with a valuation gap that may sway your choice.

  • Johnson & Johnson focuses on drug development and medical devices, with a strong medtech division.
  • Pfizer shifts focus to oncology and weight-loss treatments, investing in Seagen acquisition.
  • J&J offers steady, long-term growth and stability, while Pfizer provides higher dividend yield.

More from Sunday 22 November →